1800 244 735

Helpline (02) 9874 9777

Enemy at the gates – huntingtin disrupts nuclear transport

Exciting new studies provide evidence that a particular kind of cellular trafficking goes awry in Huntington’s Disease. Specifically, researchers have learned that traffic in and out of the cells control center – the nucleus – breaks down in HD. These findings open up new avenues for HD research.

Cellular border control

At the centre of every cell is a complex whirring hub of information storage and processing – the cell’s nucleus. The nucleus is surrounded by a double-walled border, or membrane, which separates it from the rest of the cell. The nuclear membrane allows the nucleus to safeguard its precious contents, the molecule of life, DNA.

The DNA is the instruction manual for making proteins that the cell needs to survive, grow and divide. Effectively, the nucleus needs to receive information on the status of the cell, decide which proteins need to be made and send chemical signals called mRNA (where the ‘m’ stands for messenger), back across the membrane where most of the protein production is carried out.

Overall, the nuclear membrane needs to allow useful chemicals through, while keeping potentially harmful chemicals, such as those that could damage DNA, out. To achieve this, cells have come up with a way to control the traffic crossing the membrane.

Each nucleus is studded with thousands of pores, which act as gateways in and out of the nucleus. In the same way a passport will allow a person to pass through a security gate at a border, proteins wanting to access the nucleus usually need to display a short sequence that will allow them to cross the pore. If they can present the correct sequence, a specialized protein escort will carry them across the pore. In the cell, this movement costs energy, like paying a toll. The downside of such a finely tuned border control system is that if it is compromised, it can spell disaster for the cell.

It is thought that as nuclear pores age, they lose their ability to selectively filter the traffic crossing them, which might contribute to normal human aging. People who inherit mutations disrupting the shape of the nuclear membrane age devastatingly fast, a condition known as progeria. Two recent studies from US-based teams put the focus squarely on HD, showing that the mutant huntingtin protein can cause major problems for the nuclear transport system.

Misshapen membranes

In the first study, led by Dr Jeffrey Rothstein from Johns Hopkins University, researchers looked at brain cells of aging mice, paying particular attention to the shapes of the nuclear membranes. They found that as the mice got older, the membranes became increasingly misshapen, seeming to develop buckles or creases.

They then repeated their experiment, but this time using HD mice, and found that abnormalities in the nuclear membrane were more common and appeared at an earlier age. Importantly, they saw the same effect when they compared cells from people with and without HD. These results show that HD might speed up problems that are normally seen in aging cells.

Shooting the messenger

To see if the changes in membrane shape affected transport across it, they looked at mRNA levels in the nucleus. As mentioned earlier, mRNA has to carry messages from the nucleus, across the membrane to the rest of the cell.

Normally the mRNA is found near the protein producing machinery in the cell, but in both human and mouse cells, mutant huntingtin caused mRNA to build up in the nucleus. This suggests that the transport of mRNA across the membrane might be blocked in HD.

How might this happen? The researchers looked at two proteins which normally help direct nuclear traffic, called Gle1 and RanGAP1. The first protein, Gle1, is an escort that helps mRNA get through the nuclear pores. The second, RanGAP1, ensures that there is a supply of energy available on the inside of the membrane, so that mRNAs traveling out of the nucleus can pay the ‘toll’ to get through the pores.

Both of these proteins seemed to stick to aggregates of mutant huntingtin found either in the nucleus or just outside the nucleus. This potentially stops them assisting mRNA through the pore, which might explain the nuclear mRNA build-up seen in HD cells.

Interestingly, they found that the DNA, which is normally protected by the nuclear membrane, had accumulated more damage in HD cells. However, whether this was caused by the damaged nuclei or by other mechanisms (such as those described in this recent HDBuzz article: https://en.hdbuzz.net/233) is still unclear.

Leaky pores

In the second recent study, led by Dr Clotilde Lagier-Tourenne of Massachusetts General Hospital, researchers also looked at RanGAP1. They found, like the first study, that it stuck to mutant huntingtin aggregates.

They then focussed on the nuclear pores themselves – they saw that two proteins making up the pores also stuck to huntingtin aggregates and seemed to be scattered throughout the cell rather than localised to the membrane where the pores are. This suggests that the basic structure of the pores could be compromised in HD.

The researchers next went on to look at protein cargoes that get transported through the pore and found that the cargoes tended to be misplaced on one or the other side of the nuclear membrane, suggesting that the filtering mechanism of the pores might not be working effectively in HD, leading to ‘leaky’ pores.

Can nuclear transport be rescued in HD?

Finally, the researchers tested whether they could improve nuclear transport in their experiments. They found that by artificially increasing the levels of RanGAP1 – involved in the energy toll often required to cross the pore – they could reduce some of the negative effects of HD in flies.

Additionally, they were able to use drugs targeting nuclear transport to restore normal transport across the membrane in HD-like cells that had been grown in the lab. For example, a drug called KPT-350 prevents one of the protein escorts from carrying things out of the nucleus. The drug seemed to counteract the effect of the leaky pores, restoring the balance between the cargoes inside and outside the nucleus.

In Summary

It is encouraging that two teams arrived at the same important conclusion – that HD damages nuclear transport – from different starting points. Both studies used a variety of animal models and experiments, including cells derived from HD patients, so we can be fairly confident that HD has an impact on nuclear transport.

One team demonstrated, in principle, that nuclear transport defects could be targeted with drugs. However, these experiments were carried out on cells grown in the lab and further tests need to be carried out to see whether nuclear transport can be corrected in more realistic systems such as animal models.

It is still unclear exactly how the nuclear border control is compromised in HD. While these studies show that key parts of the transport machinery, such as RanGAP1 and Gle1, can stick to aggregates of mutant huntingtin inside the nucleus, another recent study suggests that only aggregates outside the nucleus harm nuclear transport. On the other hand, the two studies in this article were able to show that problems with nuclear transport can occur without any obvious aggregates. In future work it will be important to test the relationship between aggregates and nuclear transport.

It is always exciting to discover a completely new way in which HD causes cells problems, potentially opening doors to treatments. One certainty is that these new findings will create a flurry of research activity focused on nuclear transport defects in HD. We look forward to the next study.

Latest Research Articles

Roche Phase II GENERATION HD2 study underway

Published date: 14 February, 2023

Roche released a community letter last month, detailing how their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. Learn more about what this means in this article and at the recent HDSA Research Webinar, with representatives from the company. The ups and downs of huntingtin-lowering Tominersen is a type of ... Read more

Disappointing news from Novartis about branaplam and the VIBRANT-HD trial

Published date: 9 December, 2022

The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment in Huntington’s disease (HD). This news comes following recent bad news about side effects of branaplam in HD patients, being tested in the VIBRANT-HD clinical trial, dosing of which was ... Read more

Update on the PTC Therapeutics PIVOT-HD Trial

Published date: 2 November, 2022

Recruitment of participants into the US arm of the PTC Therapeutics PIVOT-HD trial has been paused. Since this announcement, there have been a lot of different (and confusing!) headlines about the pause in recruitment. In this article, we will lay out what is going on and what this announcement means. What is the aim of ... Read more

Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials

Published date: 30 September, 2022

In the past week or so, during and following a big HD research conference, two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. First, the pharmaceutical company Roche announced plans for a new clinical trial of tominersen. Then, the genetic medicines company Wave Life Sciences shared early data showing that its ... Read more

Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps

Published date: 8 September, 2022

A group of scientists from the EPFL in Lausanne, Switzerland have published a paper in the Journal of the American Chemical Society, describing clumps made up of a fragment of the huntingtin protein. A word that’s commonly used to describe these is “aggregates.” Using very powerful microscopes, the team was able to zoom in and ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Published date: 2 September, 2022

DNA repair and CAG repeat instability The effect of HTT lowering on CAG repeat expansions Welcome to last day of the @hdfcures conference! We’ll only be sharing a few talks from today’s sessions, which focus on DNA repair. The first is from HDBuzz’s very own Jeff Carroll! Jeff will be sharing his work on HTT ... Read more